Monrol to supply Telix with Lu-177 for renal cancer trial

2020 08 20 17 37 8876 Business Handshake Man 400

Eczacıbaşı-Monrol Nuclear Products will provide lutetium-177 (Lu-177) to Telix Pharmaceuticals Limited for a phase II clinical trial of its Starlite 2 renal cancer therapy medication TLX250 (Lu-177 DOTA-girentuximab).

The trial is being conducted at Memorial Sloan Kettering Cancer Center in New York City. It is evaluating the efficacy of TLX250-targeted radiation in conjunction with the anti-PD-11 immunotherapy Opdivo2 (nivolumab) for aggressive kidney cancer. TLX250 targets a protein commonly found in patients likely to have limited response to cancer immunotherapy, Monrol and Telix said.

Memorial Sloan Kettering has financial interests in Telix, according to the two firms.

Page 1 of 436
Next Page